

Biotech Startups & Pharma

Strategy, M&A and beyond

Faculty:

Daniel Guedelha

João Santos Pereira

José Maçãs

Ana Constante







LISBOA

Summary of the course

A program tailored for individuals aspiring to enhance their expertise and proficiency within the biotech sector, especially those interested in working with the biotech ecosystem and advancing innovation within the field.

November - December 2024:

Fridays (from 5pm) and Saturdays (9am-1pm)

Face to Face at Católica Medical School

Program

This course will equip participants with a comprehensive view on Biotech & Pharma industry - from inception to business scale-up including patent strategy, clinical research & regulatory framework, funding and end-to-end M&A deal journey.

Audience

The program is suited for:

- ✓ individuals within the Life Sciences & Healthcare industry seeking to expand their knowledge of biotech startups landscape;
- ✓ leaders and managers in biotech startups;
- entrepreneurs and executives entering the Biotech and Pharma space; and/or
- ✓ professionals contemplating a career transition to a Strategy, M&A, Corporate Venture Capital or Business Development role.







Faculty



LISBOA

Anna Mattson
Partner in Strategy and Corporate Finance at
McKinsey
Global lead of Life Sciences M&A strategy and
portfolio transformation
Linkedin Profile



Helena Corte-Real
VP, Regulatory Portfolio Data & Content Senior Lead
at Roche
Previously led Regulatory Operations group within
Product Development also at Roche
Linkedin Profile



Jorge Santos Silva
Founder and CEO at MoonLake Immunotherapeutics
Previously a Senior Partner at McKinsey's and a
Leader in its Pharmaceuticals & Medical Products
Practice
Linkedin Profile



Nuno Prego Ramos
President and CEO at Valvian
Nuno was also Co-Founder and CEO of CellmAbs
(leading to Patent assignment and Licensing
agreement with BioNTech)
Linkedin Profile



Joana Piriquito Santos Founding Partner of law firm NLP Lawyer | PharmD Linkedin Profile



Daniel Guedelha
Strategic Advisor to Global Pharma and Biotech
Chief of Staff to President of Global Health and
Sustainability, Global Integration & Separation
Manager and other leadership roles in Operations
at Novartis
Linkedin Profile



Raúl Saraiva
Chief Scientific Officer & Venture Partner at 3xP
Building & investing in ventures advancing novel
therapeutics and next-gen Healthtech. Previously
Head of Operations at Aethon Therapeutics.
Linkedin Profile



Filipe Duarte
M&A Due Diligence at Novo Nordisk
Project Director working with the M&A Due
Diligence team to assist in Novo Nordisk's Business
Development agenda
Linkedin Profile



João Pereira
Executive Director at Católica Medical School
A Biostatistician, Entrepreneur and Innovation
specialist. Previously CEO of HeartGenetics and
Magnomics
Linkedin Profile



Isabel Afonso
CEO at Arcera Life Sciences
Previously Head of In-Market Brands and Business
Innovation for Novartis International and Sandoz
Head of Global Commercial Operations
Linkedin Profile



Luis Correia
Biotech consultant
(ex- Roche and ex-Credit Suisse)
Linkedin Profile



José Maçãs
Director - M&A Life Sciences & Healthcare - Deloitte
Helping Life Sciences, Medtech, Healthcare and
Consumer Health companies to build M&A
capabilities and create value from buy/sell-side
transactions, alliances and partnerships
Linkedin Profile





Course content (1/2)

Title	Invited lecturer and topics
Welcome and network (15th November; 17h00)	Daniel Guedelha, João Pereira, José Maçãs Introduce the comprehensive course program, highlighting key topics, activities, and learning objectives for participants.
	Facilitate the formation of working groups, enabling attendees to collaborate on business case analyses and discussions.
Current Pharma Industry	Anna Mattson – Partner and Global lead of Life Sciences M&A strategy and portfolio transformation at McKinsey
Strategy and M&A	Explore the evolving strategies of Pharma firms, emphasizing innovation to satisfy market demands and shareholders.
(16th November; 09h00)	Examine the imperative for M&As in Pharma, spotlighting recent trends and the allure for external acquisitions.
From Idea to Exit: Inside a	Nuno Prego Ramos - President and CEO at Valvian, previously at CellmAbs
Biotech Startup's Journey	Gain insights into the critical role of a startup biotech CEO and the path to success.
(22nd November; 17h00)	Explore key challenges faced, strategies for engaging with big Pharma, and crucial lessons learned.
Funding and Financing: From	Raúl Saraiva - Chief Scientific Officer & Venture Partner at 3xP Global
Business Angels to IPOs	Investigate diverse funding avenues within biotech, from Venture Capital to Private Equity investments.
(23rd November; 09h00)	Delve into strategies for accessing capital markets, including navigating dual-track options like sales versus listings.
Protecting Innovation:	Joana Piriquito Santos - Founding Partner at NLP
Intellectual Property	Explore the critical importance of intellectual property (IP) in the biotech sector for innovation protection.
(29th November; 17h00)	Discuss strategic approaches and timing for safeguarding biotech innovations through patents, trademarks, copyrights, and more
Business case 1 - Biotech	Business case presentation by participants
startup	Craft strategic presentations for real biotech startups, outlining funding needs, partnership opportunities, or IPO preparation.
(30th November; 09h00)	Guide participants in selecting and analyzing startup strategies aligned with raising capital, partnership, or public listing goals.





Course content (2/2)

Title	Invited lecturer and topics
Clinical Trials and Regulatory Framework: Essentials (6th December; 17h00)	 Helena Corte-Real – VP, Regulatory Portfolio Data & Content Senior Lead at Roche Examine the critical role that clinical trials play in the pharma/biotech business Understand the difference in regulatory requirements across major markets in the conduct of trials and approval of medicines
Global Biotech Hubs: The Success Story of Basel (7th December; 09h00)	 Luis Correia - Biotech consultant Case study: How Basel became Europe's leading healthcare cluster Success factors of biotech hubs: How to strengthen Portugal's standing
Big Pharma Insights: Mastering M&A Strategy, Valuation, and Execution (13th December; 17h00)	 Filipe Duarte (M&A Due Dilligence at Novo Nordisk) and José Maçãs (M&A Life Sciences at Deloitte) Explore the comprehensive phases of Pharma M&A, including due diligence, valuation, deal structuring, and licensing agreements. Gain insights into the strategic perspectives of Pharmaceutical M&A and Business Development teams during transactional processes.
Business case 2 – Portugal Global Biotech Center (14th December; 09h00)	 Business case presentation by participants Develop actionable proposals to position Portugal as a leading European hub for healthcare innovation within 5 years. Formulate strategic initiatives addressing infrastructure, investment, and ecosystem development to catalyze Portugal's biotech potential.
The history of a 3 billion dollars company (20th December; 17h00)	 Jorge Santos Silva - Founder & CEO at MoonLake Immunotherapeutics A journey from foundation, to the combination with Helix Acquisition Corp and listing in Nasdaq Company's future: Creating next-level therapies for inflammatory skin and joint diseases.
Leadership journey: Pharma, Private Equity and Sovereign Fund shareholder (21st December; 09h00)	 Isabel Afonso – CEO at Arcera Life Sciences My leadership journey in Healthcare Big Pharma and the different life science segments: from generics to highly innovative medicines Learnings from different business settings: corporate, private equity and sovereign fund shareholding





Summary

9 modules, including 2 working sessions and group work

20 Participants

~35 hours of lecturing

2'500 euros per participant





LISBOA

Thank you

